BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 3320816)

  • 1. Home care forum: cost viewpoints.
    Weinstein SM
    NITA; 1987; 10(6):401-9. PubMed ID: 3320816
    [No Abstract]   [Full Text] [Related]  

  • 2. Home intravenous drug therapy under Medicare.
    Leader S
    Pride Inst J Long Term Home Health Care; 1989; 8(3):8-14. PubMed ID: 10303820
    [No Abstract]   [Full Text] [Related]  

  • 3. Unissued rules worry home care providers.
    Lutz S
    Mod Healthc; 1989 Sep; 19(35):34, 36. PubMed ID: 10303811
    [No Abstract]   [Full Text] [Related]  

  • 4. Medicare covers home i.v. drug therapy.
    Grimaldi PL
    Nurs Manage; 1989 Dec; 20(12):14, 17. PubMed ID: 2687740
    [No Abstract]   [Full Text] [Related]  

  • 5. Reimbursement for home i.v. therapy.
    Cieplak P
    Ostomy Wound Manage; 1992 Mar; 38(2):73-5. PubMed ID: 1558637
    [No Abstract]   [Full Text] [Related]  

  • 6. Hospitals poised to offer in-home i.v. therapy.
    Robinson ML
    Hospitals; 1989 Jul; 63(14):16, 20. PubMed ID: 2666297
    [No Abstract]   [Full Text] [Related]  

  • 7. Medicare reimbursement for intravenous vancomycin at home.
    Weiss PJ; Poirier TC
    N Engl J Med; 1995 Apr; 332(15):1037. PubMed ID: 7885423
    [No Abstract]   [Full Text] [Related]  

  • 8. Home iv therapy benefit of the Catastrophic Coverage Act: it's impact on home care providers.
    Marren J; Rodgers B; Dishon M
    Pride Inst J Long Term Home Health Care; 1989; 8(3):15-8. PubMed ID: 10303818
    [No Abstract]   [Full Text] [Related]  

  • 9. Medicare program; payment for home intravenous drug therapy services--HCFA. Proposed rule.
    Fed Regist; 1989 Nov; 54(215):46938-53. PubMed ID: 10303985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. I.v. therapy: the legislative and regulatory arena.
    Hughes C; Berke D
    Caring; 1990 May; 9(5):4-7. PubMed ID: 10106790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Home infusion therapy: comparison of costs for intravenous immunoglobulin.
    Bielory L; Long GC
    N J Med; 1993 Jul; 90(7):512-5. PubMed ID: 8355890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medicare program; conditions of participation for home intravenous drug therapy providers--HCFA. Proposed rule.
    Fed Regist; 1989 Sep; 54(172):37220-38. PubMed ID: 10303828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Home infusion depresses Medical Care revenues.
    Lutz S
    Mod Healthc; 1993 Jan; 23(3):12. PubMed ID: 10123645
    [No Abstract]   [Full Text] [Related]  

  • 14. Medicare program; coverage of home intravenous drug therapy services--HCFA. Proposed rule.
    Fed Regist; 1989 Sep; 54(172):37422-38. PubMed ID: 10303831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness issues for home i.v. therapy in the United States.
    Allen R
    Hosp Formul; 1993 Jan; 28 Suppl 1():37-40. PubMed ID: 10123837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Home i.v. market is healthy hospital option.
    Souhrada L
    Hospitals; 1989 Feb; 63(3):54. PubMed ID: 2912857
    [No Abstract]   [Full Text] [Related]  

  • 17. Home i.v. therapy companies target insurers, HMOs for future growth.
    Lutz S
    Mod Healthc; 1987 Mar; 17(6):96, 99. PubMed ID: 10281052
    [No Abstract]   [Full Text] [Related]  

  • 18. Bears circle Medical Care America.
    Lutz S
    Mod Healthc; 1993 Mar; 23(10):17. PubMed ID: 10124321
    [No Abstract]   [Full Text] [Related]  

  • 19. Homedco and Abbey among companies that have viewed T2's books.
    Burns J
    Mod Healthc; 1994 Jan; 24(5):10. PubMed ID: 10131365
    [No Abstract]   [Full Text] [Related]  

  • 20. Home infusion therapy meets managed care: confrontation or cooperation.
    Winters RW
    Med Interface; 1994 Jul; 7(7):72-4, 85. PubMed ID: 10135994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.